Table 1.

Percentage expression profile of cyclin D1 and Ki-67 in cases of proliferative endometrium, simple hyperplasia, complex hyperplasia, atypical hyperplasia and endometrial carcinoma

Proliferative endometrium			Simple hyperplasia			Complex hyperplasia			Atypical hyperplasia			Endometrial carcinoma
S.No	Cyclin D	Ki-67	S.No	Cyclin D	Ki-67	S.No	Cyclin-D	Ki-67	S.No	Cyclin-D	Ki-67	S.No	Ki-67	Cyclin-D
PE 1	20	30	SH1	5	30	CH1	40	10	AH1	23	25	WDEC	20	52
PE 2	0	10	SH2	15	20	CH2	30	10	AH2	51	55	WDEC	20	55
PE 3	10	10	SH3	10	7	CH3	25	25	AH3	25	30	MAEC	2	2
PE 4	15	25	SH4	10	12	CH4	15	20	AH4	30	30	WDEC	40	70
PE 5	7	15	SH5	7	10	CH5	20	10	AH5	35	25	CCEC	18	60
PE 6	5	20	SH6	10	25	CH6	25	20	AH6	25	25	MDEC	25	60
PE 7	10	30	SH7	10	30	CH7	20	15	AH7	30	35	WDEC	80	60
PE 8	10	10	SH8	20	25	CH8	10	35				WDEC	7	10
PE 9	15	30	SH9	10	50	CH9	30	27				PDEC	60	12
PE 10	10	30	SH10	10	15	CH10	7	10				CCEC	51	80
			SH11	12	15	CH11	20	40				MDEC	40	80
						CH12	15	20				WDEC	51	55
						CH13	20	40				WDEC	80	60
												CCEC	51	60
												CCEC	80	70
												WDEC	40	51
												SPEC	7	30
												MDEC	25	35
												MDEC	80	80
												WDEC	7	20
Median	10	22.5		10	20		20	27		30	30		40	57.5

PE – Proliferative endometrium; AH – Atypical hyperplasia; CH – Complex hyperplasia; SH – Simple hyperplasia; WDEC – Well-differentiated endometrioid carcinoma; MDEC – Moderately differentiated endometrioid carcinoma; PDEC – Poorly differentiated endometrioid carcinoma; CCEC – Clear cell endometrial carcinoma; SPEC – Serous papillary endometrial carcinoma